MART-1 (27-35) (human) TFA 

MART-1 (27-35) (human) (TFA) is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) (TFA) can be used in studies related to melanoma^[1][2].

MART-1 (27-35) (human) (TFA) (10^-7-10^-5 M; 2 h at room temperature then 24 h at 4 °C) binds to purified human HLA-A2 molecules, as detected via fluorescence signal^[1].
MART-1 (27-35) (human) (TFA) (10^-5 M; overnight at 4 °C for initial complex formation) forms HLA-A2 complexes that dissociate almost completely within 24 h at 37 °C^[1].
MART-1 (27-35) (human) (TFA) (1 μg/mL; 1 h incubation with T2 cells, 4 h cytolytic assay) is recognized by human MART-1(27-35)-specific, HLA-A2-restricted TIL clones LT8, LT11, and LT12, inducing high levels of ⁵¹Cr release from T2 target cells, with half-maximal lysis of T2 cells by clone LT12 observed at 1.1 × 10^-9 M^[1].
MART-1 (27-35) (human) (TFA) (10^-10-10^-5 g/mL; 1 h) sensitizes HLA-A*0201⁺ T2 cells to lysis by CLW anti-MART-1(27-35) CD8⁺ CTL in a dose-dependent manner, with significant lysis at 10^-8 g/mL and maximum specific ⁵¹Cr release of 100% at 10^-5 g/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

813.98 (free base)

C₃₇H₆₇N₉O₁₁·xC₂HF₃O₂

Solid

White to off-white

Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val

AAGIGILTV

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Guichard G, et al. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes. J Med Chem. 2000;43(20):3803-3808.

  [2]. Loftus DJ, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med. 1996;184(2):647-657.